Asthma - Pipeline Insight, 2022
![](/report_cover/8047/asthma-pipeline-insight-2020_en.gif)
This report can be delivered to the clients within 72 hours
DelveInsight’s, “Asthma - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Asthma: Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. Symptoms of asthma vary from person to person. A person may have infrequent asthma attacks or have symptoms only at a certain time such as when exercising or may have symptoms all the time. Symptoms of asthma resemble many respiratory infections. The first step in asthma diagnosis is a careful clinical history; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on the quality of life.
'Asthma - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Asthma pipeline landscape is provided which includes the disease overview and Asthma treatment guidelines. The assessment part of the report embraces, in depth Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Asthma Emerging Drugs
Further product details are provided in the report……..
Asthma: Therapeutic Assessment
This segment of the report provides insights about the different Asthma drugs segregated based on following parameters that define the scope of the report, such as:
Asthma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Asthma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Asthma drugs.
Asthma Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Asthma - Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Asthma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Asthma: Overview
Asthma is a chronic disease that affects the airways. Asthma is characterized by inflammation and spasm of the airways. The airways are tubes that carry air in and out of the lungs. If a person has asthma, the inside walls of the airways become sore and swollen. The air passages in the lungs become narrow due to inflammation and tightening of the muscles around the small airways. This causes asthma symptoms: cough, wheeze, shortness of breath, and chest tightness. Symptoms of asthma vary from person to person. A person may have infrequent asthma attacks or have symptoms only at a certain time such as when exercising or may have symptoms all the time. Symptoms of asthma resemble many respiratory infections. The first step in asthma diagnosis is a careful clinical history; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on the quality of life.
'Asthma - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Asthma pipeline landscape is provided which includes the disease overview and Asthma treatment guidelines. The assessment part of the report embraces, in depth Asthma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Asthma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Asthma R&D. The therapies under development are focused on novel approaches to treat/improve Asthma.
- In October 2021, The board of directors of Mabpharm Limited announced that the new drug application (NDA) of CMAB007 (omalizumab), a core product of the Company, was accepted by the National Medical Products Administration of the People's Republic of China ('NMPA') for the treatment of allergic asthma, which is the first domestic allergic asthma therapeutic antibody new drug in China with NDA submitted. CMAB007 (omalizumab) is the second drug to be submitted for marketing application by the Company.
- In September 2021, Evelo Biosciences, Inc. announced that the U.S. Patent and Trademark Office has issued a new composition of matter patent (No. 11,090,341) for medicines comprising pharmaceutical compositions of Veillonella parvula bacteria. This patent is a key addition to the Company’s substantial and growing intellectual property (IP) portfolio for treatments targeting the small intestinal axis, SINTAX™.
- In November 2021, CSPC Pharmaceutical Group Limited (the “Company” announced that Shanghai JMT-BIO Technology Co., Ltd, a wholly-owned subsidiary of the Company, has entered into an agreement (the “Agreement”) with Keymed Bioscience (Chengdu) Co., Ltd. in relation to the exclusive licensing and commercialization of the product CM326 (an anti-TSLP recombinant humanized monoclonal antibody, the “Product”) in the treatment of moderate to severe asthma, chronic obstructive pulmonary disease (COPD) and other respiratory system diseases.
- In November 2021, Amgen and AstraZeneca agreed to include AMG 104 / AZD8630 in the existing collaboration agreement between the parties. AMG 104 / AZD8630 becomes part of the collaboration with the companies sharing both costs and income, with no inventor royalty.
This segment of the Asthma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Asthma Emerging Drugs
- PT-027: Avillion LLP
- MM09-MG01: Inmunotek S.L.
- FP 025: Foresee Pharmaceuticals
- GB001: Gossamer Bio
- EDP1867: Evelo Biosciences, Inc.
- TQC2731: Chia Tai Tianqing Pharmaceutical Group
Further product details are provided in the report……..
Asthma: Therapeutic Assessment
This segment of the report provides insights about the different Asthma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Asthma
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Asthma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Asthma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Asthma drugs.
Asthma Report Insights
- Asthma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Asthma drugs?
- How many Asthma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Asthma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Asthma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Asthma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Mabpharm Limited
- Avillion LLP
- GlaxoSmithKline
- Immunotek SL
- AB Science
- EMS
- AstraZeneca
- Inmunotek
- Pearl Therapeutics Inc.
- Sterna Biologics
- Verona Pharma
- MediciNova
- Foresee Pharmaceuticals
- EURRUS Biotech
- T-Balance Therapeutics
- Teva Pharmaceutical Industries
- Theravance Biopharma
- Akeso Biopharma
- Aldeyra Therapeutics
- Gossamer Bio
- Novartis Pharmaceuticals
- Trio Medicines
- Janssen Research & Development
- Cumberland Pharmaceuticals
- Concentrx Pharmaceuticals
- Tetherex Pharmaceuticals
- Genentech
- SolAeroMed
- Palobiofarma
- Sanofi
- Oneness Biotech
- Knopp Biosciences
- Keymed Biosciences
- Suzhou Connect Biopharmaceuticals
- Chiesi Farmaceutici S.p.A.
- Aquilon Pharma
- 4D Pharma Plc
- Hoffman-La-Roche
- Celltrion
- Glenmark Pharmaceuticals
- Archivel Farma
- Siolta Therapeutics
- CMAB007
- PT027
- GSK3511294
- MM09-MG01
- Masitinib
- Budesonide/Formoterol
- BGF MDI
- MM09
- PT001
- SB010
- Ensifentrine
- Bedoradrine
- FP-025
- XC8
- Tregalizumab
- TEV-53275
- TEV-48574
- TD-8236
- AK-120
- ADX-629
- GB001
- Glycopyrronium Bromide
- TR4
- MEDI 3506
- Lumicitabine
- Interferon beta-1a Nebuliser solution 48 ?g/mL
- Ifetroban
- Halix(TM) Albuterol
- SelK2
- MTPS9579A
- S1226
- PBF-680
- Rilzabrutinib
- FB825
- FB704A
- Dexpramipexole
- CSJ117
- CM310
- CJM112
- CBP-201
- AZD1402
- AS MDI
- CHF6366
- AQ001S
- MRx-4DP0004
- RG6314
- CT-P39
- GBR 310
- RUTI
- STMC-103H
Introduction
Executive Summary
Asthma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Asthma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
PT-027: Avillion LLP
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
PT001: Pearl Therapeutics (AstraZeneca)
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
FP 025: Foresee Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
AQ-001S: Aquilon Pharmaceuticals S.A
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Itolizumab (EQ001): Equillium
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
KBP7026: KBP Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Asthma Key Companies
Asthma Key Products
Asthma- Unmet Needs
Asthma- Market Drivers and Barriers
Asthma- Future Perspectives and Conclusion
Asthma Analyst Views
Asthma Key Companies
Appendix
Executive Summary
Asthma: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Asthma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
PT-027: Avillion LLP
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II/III)
Comparative Analysis
PT001: Pearl Therapeutics (AstraZeneca)
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
FP 025: Foresee Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
AQ-001S: Aquilon Pharmaceuticals S.A
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Itolizumab (EQ001): Equillium
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
KBP7026: KBP Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Asthma Key Companies
Asthma Key Products
Asthma- Unmet Needs
Asthma- Market Drivers and Barriers
Asthma- Future Perspectives and Conclusion
Asthma Analyst Views
Asthma Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Asthma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Asthma
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Asthma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Asthma
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products